ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model1

ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model1

Bibliographic Details
Main Author:	Eva Hurt-Camejo
Format:	Article
Language:	English
Published:	Elsevier 2020-03-01
Series:	Journal of Lipid Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S0022227520435126

Similar Items

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
by: Lillian Smith, et al.
Published: (2016-03-01)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023-12-01)

PCSK9 Associated Promoter Methylation Status in Patients with Hyperlipidemia
by: Samaneh Bahrami, et al.
Published: (2021-08-01)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
by: Preiss, D, et al.
Published: (2016)

ANGPTL3 impacts proteinuria and hyperlipidemia in primary nephrotic syndrome
by: Fu Zhong, et al.
Published: (2022-04-01)

ANGPTL3 gene variants in subjects with familial combined hyperlipidemia
by: A. M. Bea, et al.
Published: (2021-03-01)

Lipid-modifying agents, from statins to PCSK9 inhibitors
by: Preiss, D, et al.
Published: (2020)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
by: Christopher LaFratte, et al.
Published: (2023-09-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
by: Konstantinos Koskinas, et al.
Published: (2016-07-01)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
by: Naoto Kuyama, et al.
Published: (2021-06-01)

ANGPTL3, ANGPTL4, APOA5, APOB, APOC2, APOC3, LDLR, PCSK9, LPL gene variants and coronary artery disease risk
by: A. N. Meshkov, et al.
Published: (2022-11-01)

Novel ASO therapeutic target designed against hyperlipidemia via PCSK9 knockdown
by: Xinjian Yu, et al.
Published: (2024-01-01)

Carotid Artery Temperature Reduction with Statin Therapy in Patients with Familial Hyperlipidemia Syndromes
by: Georgios Benetos, et al.
Published: (2021-10-01)

RETRACTED ARTICLE: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

Retraction Note: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2023-05-01)

Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity
by: Ting Sun, et al.
Published: (2021-11-01)

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
by: Sliz, E, et al.
Published: (2018)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
by: Mbikay Majambu, et al.
Published: (2008-06-01)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).
by: Elisa Waldmann, et al.
Published: (2022-01-01)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
by: Elisa Waldmann, et al.
Published: (2022-01-01)

Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
by: Emily Punch, et al.
Published: (2022-02-01)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
by: Aikaterini Arida, et al.
Published: (2021-10-01)

New developments in atherosclerosis: clinical potential of PCSK9 inhibition
by: Giunzioni I, et al.
Published: (2015-08-01)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S]
by: Victor Sokolov, et al.
Published: (2019-09-01)

Aerobic Exercise Training Inhibits Neointimal Formation via Reduction of PCSK9 and LOX-1 in Atherosclerosis
by: Wei Li, et al.
Published: (2020-04-01)

ANGPTL4 sensitizes lipoprotein lipase to PCSK3 cleavage by catalyzing its unfolding
by: Anne-Marie Lund Winther, et al.
Published: (2021-01-01)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
by: Mohsin Haseeb, et al.
Published: (2023-03-01)

Hyperlipidemia, statin use and dengue severity
by: Chia, Po Ying, et al.
Published: (2018)

Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
by: Yanan Wang, et al.
Published: (2023-02-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation
by: Tóth Štefan, et al.
Published: (2020-08-01)

THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
by: Алексей Михайлович Чаулин, et al.
Published: (2019-12-01)

The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
by: Yuichi Ikegami, et al.
Published: (2018-06-01)

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar
by: Preiss, D, et al.
Published: (2020)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
by: Assunta Di Costanzo, et al.
Published: (2023-07-01)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
by: Shuai Wang, et al.
Published: (2022-10-01)

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
by: Ying Xiao, et al.
Published: (2022-11-01)